Kestra is a commercial-stage wearable cardiac-device company scaling its ASSURE wearable cardioverter defibrillator through market expansion, new territories and deeper prescriber adoption. Its prior-quarter story already featured rapid revenue growth, commercial-team expansion and improving margins, so this filing is mainly a test of whether that ramp is translating into durable operating leverage.
The quarter beat the revenue bar and lifted the full-year target. Revenue reached $31.0 million, up 60% year over year, versus a published Q1 consensus of roughly $29.0 million; the company attributed the growth to WCD market expansion, share gains, new territories, payer mix and billing improvements. FY27 revenue guidance also rose to $141 million from $137 million, implying 48% growth over FY26.
| Metric | Q1 FY27 | Prior comparison / expectation |
|---|---|---|
| Revenue | $31.0M | $19.4M prior year; ~$29.0M consensus |
| Gross margin | 56.5% | 45.7% prior year |
| GAAP net loss | $(44.1)M | $(25.8)M prior year; $(0.75) per share vs ~$0.62 loss consensus |
| Adjusted EBITDA loss | $(24.0)M | $(19.4)M prior year |
| Cash, cash equivalents and investments | $244.7M | $201.2M prior year |
| FY27 revenue guidance | $141M | Raised from $137M |
The core economics improved, but the company is still spending faster to chase growth. Gross margin expanded to 56.5% from 45.7%, a meaningful sign that volume, payer mix and cost programs are improving the business model. 〔0〕 But adjusted operating expenses rose to $44.2 million from $30.3 million as Kestra expanded commercially and accelerated R&D, leaving adjusted EBITDA losses wider at $24.0 million versus $19.4 million. 〔1〕
The headline loss overstates the operating deterioration, but cash consumption remains material. GAAP net loss included a $6.3 million debt-extinguishment charge, making the $44.1 million loss look worse than the underlying operating result; nevertheless, operating cash use was still $32.3 million and capital spending was $8.3 million. The balance sheet had $244.7 million of cash and investments, plus approximately $75 million of committed unused term-loan capacity, giving management about $320 million of stated liquidity.
Bottom line: This was a genuine growth beat with a modestly stronger outlook, and the margin trend supports the commercial ramp. The catch is that Kestra has not yet converted growth into lower losses or positive cash flow, so the business story improves more than the profitability story.
Read the original 8-K on SEC EDGAR ↗